Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 9/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 2/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.55 |
| ▸ | TUBB | P07437 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650293 | 0.84 | TYMS (1.00) | TYMSPARP1 | |
| SCHEMBL29535139 | 0.82 | KDM4E (0.66) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL7263029 | 0.82 | KDM4E (0.66) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL29901695 | 0.79 | KDM4E (0.62) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL10288872 | 0.79 | TYMS (0.72) | TYMSPARP1TUBB4ATUBBTUBA3C | |
| SCHEMBL29900526 | 0.79 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL3115005 | 0.79 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL31463101 | 0.79 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL5313776 | 0.79 | TYMS (0.72) | TYMSKDM4EHSD17B10LMNAPARP1 | |
| SCHEMBL28637729 | 0.79 | KDM4E (0.62) | TYMSKDM4EHSD17B10LMNAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230557-B | Quinazoline-substituted 1,2,3-triazole derivative, and pharmaceutical composition, preparation method and application thereof | 深圳大学 | 2023-01-06 | — | — | CN | disclosed |
| CN-114230557-A | Quinazoline-substituted 1,2, 3-triazole derivative, and pharmaceutical composition, preparation method and application thereof | 深圳大学 | 2022-03-25 | — | — | CN | disclosed |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | UBE INDUSTRIES, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| CN-1835930-A | Process for producing pyrimidin-4-one compound | UBE INDUSTRIES (JP) | 2006-09-20 | — | — | CN | disclosed |
| EP-1637523-A1 | PROCESS FOR PRODUCING PYRIMIDIN-4-ONE COMPOUND | Ube Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| CN-1474816-A | 4-amino-quinazolines | Ĭ��ר���ɷ�����˾ | 2004-02-11 | — | — | CN | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | DDC, ODC1, APRT | TYMS 6/4885KDM4E 2569/4885HSD17B10 2895/4885 |
| US-20210177851-A1 | NOVEL BENZYLAMINO SUBSTITUTED QUINAZOLINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | TYMS 3440/4885KDM4E 3689/4885HSD17B10 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.